MDT

Medtronic plc New York Stock Exchange
$125.41
Open: $126.8 High: $126.92 Low: $125.06 Close: $125.41
Range: 2021-06-23 - 2021-06-24
Volume: 4,402,549
Market: Open
Powered by Finage Stock APIDelayed data
MDT
Medtronic plc Lower Hatch Street Dublin , 2 http://www.medtronic.com
Medtronic PLC is a medical technology company. It is primarily manufactures and sells device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments.
  • CEO: Omar Ishrak
  • Employees: 86,000
  • Sector: Healthcare
  • Industry: Medical Devices
MDT News
Latest news about the MDT
  • Medtronic (MDT) Reports First Surgery With Hugo RAS System

    Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.

    View More →
  • Rite Aid CEO: Our vaccine rollout was much bigger than expected

    Rite Aid “never thought [it] would get inundated with people trying to get a vaccine,” CEO of Rite Aid (RAD) Heyward Donigan said in a discussion panel as part of the Milken Institute’s Future of Health Summit.

    View More →
  • Expect wave of severe health problem diagnoses: Labcorp CEO

    The coronavirus pandemic will leave long-lasting issues for Americans across the country, even those who might not know it yet.

    View More →
  • Medtronic Announces Real-World Data on InPen™ and Extended Infusion Set* Pivotal Trial Data at the American Diabetes Association 81st Scientific Sessions

    Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced its participation at the American Diabetes Association (ADA) 81th scientific sessions virtual meeting, June 25-29, 2021. Medtronic will be participating in this year's ADA virtual sessions with seven data presentations, a product theater, two on-demand learning sessions, and a virtual exhibit. This year Medtronic will showcase its most advanced product portfolio designed to help individuals achieve better glucose

    View More →
  • Medtronic (MDT) Gets Expanded FDA Nod for Cryoablation Catheters

    Medtronic's (MDT) Cardiac Cryoablation Catheters offer safe and effective substitute to antiarrhythmic drug therapy for the prevention of atrial arrythmia recurrence.

    View More →
  • First Procedure in the World with Medtronic Hugo™ Robotic-Assisted Surgery System Performed at Clínica Santa Maria in Chile

    Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient procedure with the Hugo™ robotic-assisted surgery (RAS) system. The robotic prostatectomy was performed June 19 by urological surgeon Ruben Olivares, M.D., at Clínica Santa Maria in Santiago, Chile.

    View More →
  • World's First Heart Valve Replacement Using Extended Reality Platform Brings the Operating Room to the Remote Surgical Specialist for Virtual Support During Live Procedures

    The Jewish General Hospital (JGH), a member facility of the West-Central Montreal Health Authority (CIUSSS), together with Auger Groupe Conseil Inc. (AGC) and Medtronic Canada ULC ― a subsidiary of Medtronic plc (NYSE:MDT) ― have pioneered the first application of the Microsoft HoloLens for use in real-time, extended reality (XR) clinical support of a minimally invasive heart procedure.

    View More →
  • Medtronic Receives FDA Expanded Approval for Arctic Front™ Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation

    Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it received U.S. Food and Drug Administration (FDA) expanded approval for the Arctic Front™ Family of Cardiac Cryoablation Catheters for the treatment of recurrent symptomatic paroxysmal atrial fibrillation (episodes that last less than seven continuous days) as an alternative to antiarrhythmic drug (AAD) therapy as an initial rhythm control strategy. The expanded indication is based on results from STOP AF First

    View More →
  • Just Four Days Till Medtronic plc (NYSE:MDT) Will Be Trading Ex-Dividend

    Medtronic plc ( NYSE:MDT ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is usually set to be...

    View More →
  • 10 Best Healthcare Stocks to Buy According to Hedge Funds

    In this article, we will take a look at some of the best healthcare stocks to buy based on the data of over 860 hedge funds tracked by Insider Monkey. You can skip our detailed analysis of the healthcare industry and go directly to see 5 Best Healthcare Stocks to Buy According to Hedge Funds. […]

    View More →
  • Should I Buy Medtronic plc (MDT)?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

    View More →
  • Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta

    Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.

    View More →
  • Medtronic Receives FDA Approval for Neurostimulator; Shares Rise 1.4%

    Shares of Medtronic (MDT) gained 1.4% after the company received approval from the U.S. Food and Drug Administration for Vanta, a recharge-free implantable neurostimulator. The neurostimulator offers personalized pain relief, broad MRI compatibility, and almost double the device life in certain settings. It also uses MDT’s AdaptiveStim technology for customized pain relief that adjusts to the patient’s body position using a built-in accelerometer. (See MDT stock analysis on TipRanks) VP and GM o

    View More →
  • Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform

    Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years. At comparable settings, the Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices.1,2 It also utilizes Medtronic's proprietary AdaptiveStim™ technology for personalized pain

    View More →
  • Medtronic's (MDT) STROKE AF Trial Outcome Backs ICM Progress

    STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.

    View More →
  • Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod

    Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.

    View More →
  • Abbott (ABT) Confirms Capacity to Support MCS Devices Demand

    Abbott's (ABT) HeartMate 3 heart pump can significantly enhance quality of life and reduce adverse events.

    View More →
  • Study Shows Medtronic's Cardiac Monitor Tops Standard Care for Atrial Fibrillation Detection

    Medtronic plc (NYSE: MDT) has announced clinical trial results from the STROKE atrial fibrillation (AF) trial assessing its Reveal LINQ Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats compared to standard of care. The findings were published in the Journal of the American Medical Association. The study evaluated 496 patients, including 284 large vessel and 208 small vessel stroke patients. At 12 months, AF was detected in 12.1% of patients in the ICM arm compared to 1.8% in the st

    View More →
  • Medtronic Insertable Cardiac Monitor Detects Significantly Higher Rates of Atrial Fibrillation in Large and Small Vessel Stroke Patients Compared to Standard of Care

    Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal LINQ™ Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats, otherwise known as atrial fibrillation (AF), in both large and small vessel stroke patients compared to standard of care. The findings were published in the June 1, 2021 issue of the Journal of the American Medical Association (JAMA).

    View More →
  • FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy

    Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead System used for Deep Brain Stimulation (DBS) therapy. SenSight is the first-of-its-kind DBS directional lead that combines the benefits of directionality with the power of sensing, allowing physicians to deliver precise, patient-specific DBS therapy for the treatment of some symptoms associated with movem

    View More →